Abstract
Cytokines are critical mediators of protective host responses, including defense against microbial invasion and tumorigenesis. However, the production of specific proinflammatory cytokines must be tightly regulated and compartmentalized to prevent the overzealous expression of these molecules that can culminate in unabated inflammation and tissue injury. Cytokine production and/or biologic effects can be inhibited by a variety of endogenous molecules, including anti-inflammatory cytokines, soluble cytokine receptors, and receptor antagonist proteins. Additionally, synthetic molecules have been constructed to selectively block the synthesis, post-translation processing, or receptor binding of proinflammatory cytokines. Relevant anti-inflammatory cytokines and cytokine inhibitors (both endogenous and synthetic) will be the subject of this review, with a particular emphasis on those anti-inflammatory cytokines and cytokine inhibitors that have been used experimentally or clinically in the treatment of diseases that are believed to be mediated by excessive proinflammatory cytokine responses.
Keywords: Antiinflammatory Cytokines, Antagonists, Microbial Invasion, tumorigenesis, receptor, proteins, endogenous synthetic, Regulation, Sepsis syndrome, rhematoid arthritis RA, Interleukin 4 IL4, autoimmune disease, Proinflammatory, Necrosis Factor, Pathogenesis, Blockade, Chemokines, Transcriptional factor Inhibitors
Current Pharmaceutical Design
Title: Anti-inflammatory Cytokines and Cytokine Antagonists
Volume: 6 Issue: 6
Author(s): Theodore J. Standiford
Affiliation:
Keywords: Antiinflammatory Cytokines, Antagonists, Microbial Invasion, tumorigenesis, receptor, proteins, endogenous synthetic, Regulation, Sepsis syndrome, rhematoid arthritis RA, Interleukin 4 IL4, autoimmune disease, Proinflammatory, Necrosis Factor, Pathogenesis, Blockade, Chemokines, Transcriptional factor Inhibitors
Abstract: Cytokines are critical mediators of protective host responses, including defense against microbial invasion and tumorigenesis. However, the production of specific proinflammatory cytokines must be tightly regulated and compartmentalized to prevent the overzealous expression of these molecules that can culminate in unabated inflammation and tissue injury. Cytokine production and/or biologic effects can be inhibited by a variety of endogenous molecules, including anti-inflammatory cytokines, soluble cytokine receptors, and receptor antagonist proteins. Additionally, synthetic molecules have been constructed to selectively block the synthesis, post-translation processing, or receptor binding of proinflammatory cytokines. Relevant anti-inflammatory cytokines and cytokine inhibitors (both endogenous and synthetic) will be the subject of this review, with a particular emphasis on those anti-inflammatory cytokines and cytokine inhibitors that have been used experimentally or clinically in the treatment of diseases that are believed to be mediated by excessive proinflammatory cytokine responses.
Export Options
About this article
Cite this article as:
Standiford J. Theodore, Anti-inflammatory Cytokines and Cytokine Antagonists, Current Pharmaceutical Design 2000; 6 (6) . https://dx.doi.org/10.2174/1381612003400533
DOI https://dx.doi.org/10.2174/1381612003400533 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry Iodine-Refractory Thyroid Carcinoma
Reviews on Recent Clinical Trials Medicinal Chemistry of Quinolines As Emerging Anti-inflammatory Agents: An Overview
Current Medicinal Chemistry Different Sides of Depression in the Elderly: An In-depth View on the Role of Aβ Peptides
Current Medicinal Chemistry Suppression of HIV Replication In Vitro by CpG and CpG Conjugated to the Non Toxic B Subunit of Cholera Toxin
Current HIV Research The Relevance of Microdialysis for Clinical Oncology
Current Clinical Pharmacology Streptococcal Collagen-like Protein 1 Binds Wound Fibronectin: Implications in Pathogen Targeting
Current Medicinal Chemistry Data Reduction Methods for Application of Fluorescence Correlation Spectroscopy to Pharmaceutical Drug Discovery
Current Pharmaceutical Biotechnology Drugs of Abuse and Oxidative Stress in the Brain: From Animal Models to Human Evidence
Mini-Reviews in Organic Chemistry Cytokine-Induced Depression: Current Status and Novel Targets for Depression Therapy
CNS & Neurological Disorders - Drug Targets Current Status and Future Perspectives of Chemoprevention in Head and Neck Cancer
Current Cancer Drug Targets Extracts of Bacopa monnieri (L) Pennell Down-Regulate the Expression of Leukotriene C<sub>4</sub> Synthase mRNA in HL-60 Cells and Suppress OVAInduced Inflammation in BALB/c Mice
Current Bioactive Compounds Diabetes-Induced Alterations in Renal Medullary Microcirculation and Metabolism
Current Diabetes Reviews A Risk Assessment Tool for the Virtual Screening of Metal Oxide Nanoparticles through Enalos InSilicoNano Platform
Current Topics in Medicinal Chemistry The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery The Relevance of Protein-Ligand Interaction Profiles in Computer-Aided Novel Compound Design and Applications
Current Bioinformatics Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Wound with Diabetes: Present Scenario and Future
Current Diabetes Reviews A Review on Response of Immune System in Spinal Cord Injury and Therapeutic Agents useful in Treatment
Current Pharmaceutical Biotechnology EQCM Biosensors Based on DNA Aptamers and Antibodies for Rapid Detection of Prions
Protein & Peptide Letters